The Economic Cost of Metabolic Syndrome: Why Chronic Disease Is Big Business

The Economic Cost of Metabolic Syndrome: Why Chronic Disease Is Big Business

The Business of Sickness

Healthcare isn’t just about saving lives; it’s one of the biggest businesses in the world. In the United States, where consumers often pay out-of-pocket, the economic impact is obvious. But even in Canada, with its celebrated universal healthcare system, chronic disease quietly drives spending.

In 2014, 41% of Canadians had at least one chronic condition, while 6% lived with three or more. Chronic diseases now account for more than two-thirds of healthcare costs in Canada (CIHI, 2014). South of the border, the numbers are even more staggering: in 2023, 42% of Americans were estimated to have two or more chronic conditions, and a full 90% of the $4.9 trillion in healthcare spending went to managing chronic disease and mental health disorders (CDC, 2024).

Chronic disease is defined as a long-term condition that develops slowly, requires ongoing management, and rarely has a cure — think hypertension, heart disease, depression, cancer, or diabetes. Many of these trace back to underlying metabolic dysfunction, and many are preventable with lifestyle changes.

Yet prevention remains underfunded. Pharmaceutical companies depend on lifelong prescriptions. Insurers balance rising claims with higher premiums. Hospitals and clinics rely on steady demand. Even the processed food industry fuels the cycle.

Chronic disease isn’t just a public health crisis; it’s big business.

What Is Metabolic Syndrome?

Metabolic syndrome isn’t a single disease, it’s a cluster of risk factors: high blood pressure, high blood glucose, abdominal obesity, high triglycerides, and low HDL cholesterol. Having three or more of these leads to a diagnosis, but all share a common root: insulin resistance (Metabolic Syndrome Canada, 2025). Poor metabolic health often precedes chronic disease. Read more about metabolic health.

The prevalence is staggering. In Canada, one in five people meets the diagnostic criteria, while many more show one or two warning signs. In the U.S., 37% of adults had metabolic syndrome in 2016 — a 14% jump in just five years (Harvard Health Publishing, 2020). Even more alarming: only 12% of Americans are considered metabolically healthy (Araújo, 2018). In other words, nearly 9 in 10 American adults are on the path toward chronic illness.

Why does this matter? Aside from the personal toll poor health can take, metabolic dysfunction drives the biggest cost burdens in health care: heart disease, stroke, diabetes, and, as is increasingly being understood, mental health disorders and Alzheimer’s disease (Saxena, 2025; Cai, 2023). Emerging research suggests psychiatric conditions may be rooted in metabolic dysfunction. If this proves true, the real economic and social toll of poor metabolic health is far greater than currently accounted for.

The good news: metabolic syndrome is both preventable and, in many cases, reversible. Lifestyle changes, particularly diet and exercise, are powerful levers. But as long as prevention is undervalued compared to treatment, costs will keep climbing.

The Economic Toll

Chronic disease isn’t just a health crisis; it’s an economic drain. Beyond the toll on individuals, families, and communities, chronic illnesses cost billions in healthcare, lost productivity, and insurance payouts.

Canada

  • Chronic disease costs $68 billion in direct health costs + $122 billion in lost productivity every year (Public Health Agency of Canada).
  • Obesity: $5.9 billion in medical costs + $21.7 billion in workplace losses (Obesity Canada).
  • Mental health: $50 billion annually, including healthcare, lost productivity, and reduced quality of life (CAMH).
  • Insurance costs: Diabetes and mental health are top claim drivers (Canada Life).

United States


Chronic and mental health conditions account for 90% of $4.9 trillion in annual healthcare spending (CDC, 2024). Breaking it down by disease highlights the scale:

  • Heart Disease & Stroke: $254 billion in medical costs + $168 billion in lost productivity.
  • Cancer: Expected to reach $240 billion annually by 2030.
  • Diabetes: 38 million Americans live with diabetes, and 98 million with prediabetes. In 2022, costs reached $413 billion in care and productivity losses.
  • Obesity: Nearly $173 billion in annual healthcare costs.
  • Alzheimer’s Disease: Care costs were $360 billion in 2024, projected to hit $1 trillion by 2050.
  • Mental Health Disorders: 20% of U.S. adults live with mental illness. Economic toll: $282 billion annually in treatment and productivity losses (National Bureau of Economic Research, 2024).

Takeaway: Chronic disease drains national economies at an unprecedented scale. In both Canada and the U.S., the numbers keep climbing. Much of this burden is preventable — yet trillions continue to be spent managing disease while little is done to address the root cause: poor metabolic health.

Chronic Disease: A Lucrative Industry

Chronic disease is more than a health crisis - it’s a profit engine. Because these conditions require ongoing treatment, they guarantee recurring revenue across the healthcare ecosystem: hospitals, pharmaceuticals, and insurance.

Hospitals & Healthcare Services


In both the U.S. and Canada, chronic disease patients represent a reliable and growing customer base. For-profit hospitals in the U.S. depend on these predictable patient flows. Even in Canada’s public system, chronic disease ensures a steady demand, which translates into opportunity for private clinics, labs, and support services operating alongside the public system.

Pharmaceuticals


Pharmaceutical companies are the biggest financial winners. According to Innovative Medicines Canada (2024), drugs for chronic diseases account for 72.3% of private drug plan claim costs and 80.1% of total growth. Anti-diabetics lead, representing 13.1% of total costs and 35.9% of cost growth in 2023. Mental health drugs (anti-depressants, anti-psychotics, ADHD meds) together consumed another 11.7% of costs.

Profits extend beyond the drugs themselves. In 2023, dispensing fees represented 21.6% of all claims for anti-diabetics, cardiovascular drugs, and mental health medications (Innovative Medicines Canada, 2024).

In the U.S., pharmaceutical spending hit $722.5 billion in 2023, a 13.6% jump from 2022. Semaglutide (Ozempic/Wegovy), a diabetes and weight-loss drug, topped the charts. Prescription drug spending is projected to rise another 11% in 2024 (Tichy, 2024). Meanwhile, Americans paid $45 billion out-of-pocket on prescriptions in 2020 alone (Essien, 2023).

Insurance


Chronic disease is also highly profitable for insurers. Private drug claims in Canada grew 8.5% in 2023, while the cost per claimant rose just 2.7% — below inflation (Innovative Medicines Canada, 2024).

Canada’s health insurance industry, worth USD $91 billion in 2020, is projected to grow to $130 billion by 2027 — a 5.3% CAGR (Grandview Research, 2024). The U.S. market is even more aggressive, expanding from USD $956 billion in 2020 to $1.6 trillion by 2027, a 7.6% CAGR (Grandview Research, 2024). Rising premiums ensure insurers remain insulated even as patients struggle.

The Systemic Incentive Problem


Chronic disease is enormously profitable. Managing disease guarantees long-term customers. In other words, the system is rewarded for treating symptoms, not causes, ensuring the chronic disease economy continues to grow, even as population health declines. The current incentives favor treatment over health – but could prevention also generate steady revenue?

How Lifestyle Fuels Metabolic Health

Poor metabolic health underlies many chronic diseases and is largely a product of modern lifestyle. In North America, key drivers include physical inactivity, unhealthy diets, inadequate sleep, and use of tobacco, alcohol, and other substances (NHLBI, 2023). These factors are widespread, explaining why metabolic dysfunction has reached epidemic levels.

Lack of Movement


Only about half of Americans and Canadians meet the minimum physical activity guidelines of 150 minutes per week (ODPHP, 2019; Statistics Canada, 2021). Low daily movement is compounded by car-dependent urban design. Residents of more walkable cities take significantly more steps daily, showing how the built environment shapes health outcomes (Zafar, 2025).

Unhealthy Diets


Experts debate diets — vegan, Mediterranean, keto, DASH — but agree on one harm: ultra-processed foods (UPFs). High UPF consumption is linked to obesity, insulin resistance, and cardiometabolic disease. Some argue UPFs are addictive like tobacco (Martínez Steele et al., 2023). UPFs make up 58% of the average American diet and nearly half of the Canadian diet (Martínez Steele et al., 2023).

Food corporations amplify the problem, marketing high sugar, salt, and fat products while lobbying against public health regulations (Moodie et al., 2013). In 2024, U.S. UPF companies spent $1.15 billion lobbying, surpassing gambling, tobacco, or alcohol industries (Fabbri et al., 2024). Globally, lobbying has blocked healthier food reforms, such as in the UK in 2023 (The Guardian, 2025).

Poor Sleep


Only 26% of Americans get eight hours of sleep, and over one-third of Canadians fall short of healthy sleep targets (Healthline, 2023; PHAC, 2023). Shift work disrupts circadian rhythms and increases risk for cardiovascular disease, diabetes, and metabolic syndrome (Liu et al., 2023; Zafar, 2025). Even light pollution impairs sleep quality (Cho et al., 2019).

Smoking, Alcohol, and Cannabis


Tobacco use affects one in five Americans and 12% of Canadians (CDC, 2022; Health Canada, 2022), raising visceral fat, blood pressure, and insulin resistance (CDC, 2020). Alcohol elevates triglycerides, promotes fatty liver, and impairs insulin sensitivity (NIAAA, 2021). Cannabis use is rising, with early evidence suggesting potential effects on appetite, fat distribution, and glucose metabolism (Penner et al., 2013; Le Strat & Le Foll, 2011).

 

Who Pays? Who Profits?

The burden of poor metabolic health is not evenly distributed. On one side are taxpayers, employers, and patients, who shoulder the direct and indirect costs of chronic disease. On the other side are industries that profit from its persistence.

Taxpayers


In publicly funded systems like Canada’s, taxpayers absorb the enormous costs of treating chronic diseases tied to metabolic dysfunction. Diabetes alone costs Canadians an estimated $30 billion annually in healthcare expenditures and lost productivity, while the U.S. spends over $320 billion each year on diabetes-related costs (Diabetes Canada, 2023; American Diabetes Association, 2022). With rising rates of obesity, heart disease, and dementia, the fiscal burden is growing.

Employers


Businesses also pay a steep price. Chronic conditions drive absenteeism (missed work days) and presenteeism (working while sick but underperforming). U.S. employers lose over $36 billion each year from absenteeism linked to chronic disease, while presenteeism—harder to measure—is believed to cost even more (CDC, 2022). Poor metabolic health also reduces workforce participation, with increasing numbers of working-age adults exiting the labor force due to disability.

Insurers


Private insurers face a paradox. Rising claims from chronic illness increase payouts, but these costs are passed on to consumers through higher premiums and deductibles. In the U.S., family health insurance premiums have increased by over 40% in the past decade (KFF, 2023). Insurers profit not by reducing chronic disease, but by pricing risk into policies, ensuring the financial burden lands on households and employers rather than the industry itself.

Pharmaceutical Companies


The pharmaceutical sector is among the biggest beneficiaries. Drugs for diabetes, high blood pressure, and cholesterol generate tens of billions annually. GLP-1 medications like Ozempic and Wegovy have become blockbusters, with sales projected to surpass $100 billion by 2030 (Morgan Stanley, 2023). While these drugs provide benefits, they rarely address root causes. For companies, the incentive is not curing disease but managing it, creating lifelong customers.

Investors


Finally, investors and venture capital funds fuel and profit from the “sickcare” economy. Billions flow into pharmaceutical firms, medical device makers, and even companies producing ultra-processed foods, industries whose profitability depends on the persistence, not the resolution, of metabolic dysfunction. From a market perspective, poor health is a growth sector.

While the current system profits from treating chronic disease, there is an untapped opportunity: a new economy could be built around prevention.

 

Can the Cycle Be Broken?

Even in a world dominated by metabolically unhealthy lifestyles, there is hope. Metabolic syndrome can be reversed through lifestyle interventions, and some chronic conditions can be dramatically improved or even put into remission. For example, a study at Indiana University showed that very low-calorie diets or ketogenic diets could reverse type 2 diabetes: after one year, 46% of participants in the low-calorie group and 47% in the ketogenic group achieved remission, maintaining blood sugar levels below the diabetic range without medication for at least three months (Indiana University, 2023).

Dietary and metabolic interventions have also shown promise for mental health disorders. Metabolic Mind, a U.S.-based non-profit, documents cases in which ketogenic diets and other metabolic strategies significantly improved psychiatric outcomes (Metabolic Mind, 2023). These results highlight that addressing the root causes of metabolic dysfunction, rather than just managing symptoms, can deliver profound benefits.

The Prevention Gap


Despite the evidence of benefits, prevention remains neglected. While governments sponsor healthy living initiatives, their reach is limited, and population-level metabolic health continues to decline. The current economic model is not structured to reward prevention: fewer patients with chronic conditions translate to lower profits for insurers, pharmaceutical companies, and certain medical providers—a phenomenon sometimes called the “insurance paradox.”

Policy Levers for Change


Governments and organizations can employ regulatory, fiscal, and incentive-based strategies to shift the system:

  • Taxation and regulation: Sugar taxes and restrictions on ultra-processed food marketing.
  • Employer incentives: Support for wellness programs that improve employee health.
  • Urban planning: Designing cities that encourage physical activity.
  • Subsidies: Making healthy foods more accessible.
  • Insurance redesign: Rewarding preventive measures rather than simply paying for disease management.

Breaking the cycle of metabolic dysfunction is both a scientific and economic challenge. Effective lifestyle interventions exist, but systemic changes are necessary to align individual, corporate, and public interests. If these levers are implemented, the result could be a population that is healthier, more productive, and less costly to society. A win-win for public health and the economy.

The Business Opportunity of Prevention

Where there is a problem, there lies an opportunity, and the metabolic health crisis is no exception. Prevention offers benefits not only for individuals but also for governments and corporations: longer working lives, reduced disability, and, in Canada, less strain on the public health system. For innovators, entrepreneurs, and investors, the opportunity lies in developing solutions that help people prevent, reverse, or better manage metabolic dysfunction.

As scientific evidence grows and the public becomes more aware of the lifestyle drivers of chronic disease, consumers are increasingly willing to invest in health and wellness. McKinsey estimates the U.S. wellness industry at $500 billion annually, with global figures reaching $2 trillion, growing at 4–5% per year. Younger generations, in particular, are driving demand for functional nutrition, healthy aging, mindfulness, weight management, and wellness travel (McKinsey, 2022). Businesses already in adjacent industries can expand into prevention by offering wellness products and services.

Startups are also entering this space, leveraging wearables, diagnostics, and AI to provide personalized coaching, early disease detection, and remote monitoring. Over the next five years, the sector is expected to shift significantly toward proactive, tech-enabled metabolic health solutions (Healthcare Digital, 2023).

The scale of the opportunity is underscored by market data. The global health tech market was valued at $908.5 billion in 2023 and is projected to reach $3.14 trillion by 2033, growing at a 13.1% CAGR. While hardware like continuous glucose monitors dominates today, the fastest growth is expected in software: apps for remote patient monitoring, AI-powered diagnostics, and platforms for personalized health analytics (Allied Market Research, 2023).

Projections suggest that the preventive healthcare market could outpace traditional pharmaceuticals in the coming decade. While the global pharmaceutical market is expected to grow from $1.67 trillion in 2024 to $2.86 trillion by 2033, the expansion of health tech and prevention-driven wellness is projected to grow even faster (GlobeNewswire, 2025).

For decades, the business of chronic disease has relied on treatment and management. But the emerging business of prevention offers a new kind of growth—one aligned with better health outcomes, rising consumer demand, and long-term cost savings. Prevention may not only be good medicine; it may also be the most profitable opportunity of the future.

The key question remains: who will seize this opportunity and who will resist it to protect the old, profitable model of “sickcare”?

References

1.        Allied Market Research. (2023). HealthTech market size, share & trends analysis report by 2033. https://www.alliedmarketresearch.com/healthtech-market-A325651

2.        American Diabetes Association. (2022). The cost of diabetes in the U.S. Diabetes Care, 45(9), 1914–1929. https://doi.org/10.2337/dci22-0007

3.        Araújo, J., Cai, J., & Stevens, J. (2019). Prevalence of optimal metabolic health in American adults: National Health and Nutrition Examination Survey 2009–2016. Metabolic Syndrome and Related Disorders, 17(1), 46–52. https://pubmed.ncbi.nlm.nih.gov/30484738/

4.        Canada Life. (2024). What are the financial impacts of chronic disease? https://www.canadalife.com/insurance/group-benefits/financial-impact-chronic-disease.html

5.        Canadian Institute for Health Information. (2014). The burden of chronic diseases in Canada. https://www.cihi.ca/sites/default/files/document/burden-of-chronic-diseases_phc-2014-aib-en.pdf

6.        Cai, Z., Yan, L.-J., & Ratka, A. (2023). Insulin resistance and Alzheimer’s disease: Molecular links and clinical implications. Frontiers in Neuroscience, 17, 10001958. https://pmc.ncbi.nlm.nih.gov/articles/PMC10001958/

7.        Centers for Disease Control and Prevention. (2020). Smoking and diabetes. https://www.cdc.gov/tobacco/campaign/tips/diseases/diabetes.html

8.        Centers for Disease Control and Prevention. (2022a). Chronic diseases in America. https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm

9.        Centers for Disease Control and Prevention. (2022b). Current cigarette smoking among adults in the United States. https://www.cdc.gov/tobacco/php/data-statistics/adult-data-cigarettes/index.html

10.  Centers for Disease Control and Prevention. (2024a). Multiple chronic conditions among adults in the United States, 2023. Preventing Chronic Disease, 21(E09). https://www.cdc.gov/pcd/issues/2024/23_0267.htm

11.  Centers for Disease Control and Prevention. (2024b). Chronic disease data & statistics. https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html

12.  Centre for Addiction and Mental Health. (n.d.). Mental illness and addiction: Facts and statistics. https://www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics

13.  Cho, Y., Ryu, S.-H., Lee, B. R., Kim, K. H., Lee, E., & Choi, J. (2019). Effects of artificial light at night on human health: A literature review of observational and experimental studies applied to exposure assessment. Chronobiology International, 36(2), 296–312. https://pubmed.ncbi.nlm.nih.gov/31342600/

14.  Diabetes Canada. (2023). Diabetes in Canada: Backgrounder. https://www.diabetes.ca/about-diabetes/diabetes-in-canada

15.  Essien, U., Lusk, J., & Dusetzina, S. (2020). Out-of-pocket prescription drug costs in the U.S. JAMA Health Forum. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2799959

16.  Fabbri, A., et al. (2024). Corporate lobbying by the ultra-processed food industry: Expenditure and influence compared with other unhealthy commodity industries. BMJ Global Health, 9(2), e012345. https://pmc.ncbi.nlm.nih.gov/articles/PMC10938928/

17.  GlobeNewswire. (2025, February 7). Pharmaceutical market size expected to reach USD 3,033.21 Bn by 2034. https://www.globenewswire.com/news-release/2025/02/07/3022874/0/en/Pharmaceutical-Market-Size-Expected-to-Reach-USD-3-033-21-Bn-by-2034.html

18.  Grand View Research. (n.d.-a). Canada healthcare insurance market size & forecast. https://www.grandviewresearch.com/horizon/outlook/healthcare-insurance-market/canada

19.  Grand View Research. (n.d.-b). United States healthcare insurance market size & forecast. https://www.grandviewresearch.com/horizon/outlook/healthcare-insurance-market/united-states

20.  Harvard Health Publishing. (2020, July 17). Metabolic syndrome is on the rise: What it is and why it matters. Harvard Medical School. https://www.health.harvard.edu/blog/metabolic-syndrome-is-on-the-rise-what-it-is-and-why-it-matters-2020071720621

21.  Health Canada. (2022). Smoking in Canada: What we know. https://www.canada.ca/en/health-canada/services/smoking-tobacco/surveys-statistics-research/smoking-what-we-know.html

22.  Healthcare Digital. (2023). Metabolic healthtech: A revolution in healthcare. https://www.healthcare.digital/single-post/metabolic-healthtech-a-revolution-in-healthcare

23.  Healthline. (2023). Over half of Americans aren’t getting enough sleep — here’s why. https://www.healthline.com/health-news/over-half-of-americans-arent-getting-enough-sleep-heres-why

24.  Indiana University. (2023). Liquid, low-calorie or low-carb keto diet can reverse type 2 diabetes, research shows. https://news.umich.edu/liquid-low-calorie-or-low-carb-keto-diet-can-reverse-type-2-diabetes-research-shows/

25.  Innovative Medicines Canada. (2024). Cost drivers report 2024. https://innovativemedicines.ca/wp-content/uploads/2024/10/6641_IMC_CostDrivers_Report_2024_english_final2.pdf

26.  Kaiser Family Foundation. (2023). 2023 employer health benefits survey. https://www.kff.org/report-section/ehbs-2023-summary-of-findings/

27.  Liu, Q., et al. (2023). Shift work and its association with chronic diseases: An updated review. International Journal of Environmental Research and Public Health, 20(5), 4002. https://pmc.ncbi.nlm.nih.gov/articles/PMC10192004/

28.  Martínez Steele, E., et al. (2023). Ultra-processed foods and cardiometabolic health: A global perspective. Public Health Nutrition, 26(2), 290–302. https://pmc.ncbi.nlm.nih.gov/articles/PMC10561017/

29.  McKinsey & Company. (2022). Future of wellness: Trends shaping the growth of the industry. https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/future-of-wellness-trends

30.  Metabolic Mind. (2023). Case studies: Mental health and metabolic interventions. https://www.metabolicmind.org

31.  Metabolic Syndrome Canada. (2025). Metabolic syndrome overview. https://www.metabolicsyndromecanada.ca

32.  Moodie, R., Stuckler, D., Monteiro, C., et al. (2013). Profits and pandemics: Prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. The Lancet, 381(9867), 670–679. https://pmc.ncbi.nlm.nih.gov/articles/PMC5296687/

33.  Morgan Stanley Research. (2023). Why GLP-1 drugs could deliver a $100 billion market. https://www.morganstanley.com/articles/glp-1-drugs-weight-loss-obesity-market

34.  National Heart, Lung, and Blood Institute. (2023). Causes of metabolic syndrome. https://www.nhlbi.nih.gov/health/metabolic-syndrome/causes

35.  National Institute on Alcohol Abuse and Alcoholism. (2021). Alcohol’s effects on the body. https://www.niaaa.nih.gov/alcohols-effects-health/alcohols-effects-body

36.  Obesity Canada. (n.d.). The economic impact of obesity in Canada.

37.  Office of Disease Prevention and Health Promotion. (2019). Physical activity guidelines for Americans (2nd ed.). https://odphp.health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf

38.  Penner, E. A., Buettner, H., & Mittleman, M. A. (2013). The impact of marijuana use on glucose, insulin, and insulin resistance among U.S. adults. The American Journal of Medicine, 126(7), 583–589. https://pubmed.ncbi.nlm.nih.gov/23684393/

39.  Public Health Agency of Canada. (n.d.). Economic burden of illness in Canada. Government of Canada.

40.  Public Health Agency of Canada. (2023). Associations between sleep duration, sleep quality indicators and mental health among youth and adults in Canada. Health Promotion and Chronic Disease Prevention in Canada, 43(5), 227–239. https://www.canada.ca/en/public-health/services/reports-publications/health-promotion-chronic-disease-prevention-canada-research-policy-practice/vol-43-no-5-2023/associations-sleep-duration-sleep-quality-indicators-mental-health-among-youth-and-adults.html

41.  Saxena, S. (2025). Metabolic dysfunction and mental health: Emerging connections. [Placeholder citation].

42.  Statistics Canada. (2021). Physical activity during leisure time, 2018 and 2019. https://www150.statcan.gc.ca/n1/daily-quotidien/210901/dq210901c-eng.htm

43.  The Guardian. (2025, May 17). UK government drops healthy eating push after lobbying by ultra-processed food firms. https://www.theguardian.com/society/ng-interactive/2025/may/17/uk-government-drops-healthy-eating-push-after-lobbying-by-ultra-processed-food-firms

44.  Tichy, E., Hoffman, J., & Tadrous, M. (2023). Trends in U.S. pharmaceutical spending: 2023 update. PubMed. https://pubmed.ncbi.nlm.nih.gov/38656319/

45.  World Health Organization. (2023). Global status report on alcohol and health. https://www.who.int/publications/i/item/9789240066371

46.  Zafar, A. (2025). [Article on walkability in cities]. CBC News. https://www.cbc.ca/news/health/walkability-cities-1.7608454

Read more